Participated · Series A · Mar 2026

Founded in 2018, Scone develops and operates virtual intellectual property by combining in-house 3D motion-capture technology with live-streaming production tools. The company has launched roughly 40 virtual characters, including the VTuber group “Meechu,” giving it one of the largest virtual character portfolios in Korea. Scone’s model allows human artists to co-create content while the company centrally manages the IP, generating revenue through live donations, merchandise, advertising, and secondary content adaptations. In 2024, revenue from its virtual IP division grew more than four-fold year over year. With fresh capital, Scone plans to extend its IP into games, web novels, webtoons, AI chatbots, and trading card games while also pursuing virtual IP partnerships in Japan, China, and Taiwan. Ongoing collaborations with past strategic investors Naver D2SF and SM Culture Partners are expected to accelerate these initiatives. The company positions itself as a platform enabling creators in overlooked sectors to establish new stages through virtual technology.

Participated · Series B · Aug 2025

Modhaus operates a multi-artist IP system and the fan-participation platform Cosmo, which enables fans to influence artist decisions such as title songs, activity units, and concert set lists. The company manages artist IPs including TripleS, Artemis, and IDENTI and reported ₩32.3 billion in revenue in 2025 with annual album sales totaling 1.16 million. Notable releases cited include TripleS’s third full album 'Love & Pop pt. 1' (560,000 initial copies) and IDENTI’s third EP 'itsnotover' (580,000 initial copies). Cosmo has recorded 530,000 cumulative subscribers, 170,000 monthly active users, and 20 million cumulative copies of its digital photocard product 'Objekt.' Artemis completed a 28-city world tour, contributing to overseas fandom expansion. Modhaus plans to grow new artist IP, proceed with IDENTI’s full 24-member activities and new artist launches, and upgrade Cosmo’s overseas services.

Led · Series B · Aug 2024

Blimonkeys' Macaron platform is a one‑stop retail service that supports Korean beauty brands' entry, distribution, sales and marketing in India. The platform offers community features and product trial programs and lists roughly 380 Korean brands for purchase. Macaron began service in July 2019 and has accumulated about 750,000 registered users with MAU of 700,000. The business reached its first monthly profit in October 2022 and has been growing roughly threefold year over year. The company has conducted over 60 Indian cosmetics certifications and reduced certification lead time from more than six months to about 45 days through its own systems. It has signed as a key distributor with some 60 K‑beauty brands and plans to use the momentum to further accelerate Korean brands' expansion into India.

Participated · Series B · Jul 2024

딜리버스 operates 딜리래빗, an AI-driven logistics service that applies a deep-learning Dynamic Clustering technique to optimize delivery routes based on daily distribution and delivery-impacting data. The service lets e-commerce companies keep their existing warehouses while offering guaranteed same-day arrival—typically within seven hours in Seoul and the greater metropolitan area—at costs comparable to regular parcel rates. 딜리버스 says its approach halves the delivery process compared with traditional couriers, enabling fast delivery and returns at lower cost. Since launching 딜리래빗 in May 2022 the company has signed about 40 client companies and achieved over 98% on-time delivery for overall volume. In the first half of this year, revenue more than doubled year-over-year. Notable clients include 지그재그 (Zigzag), 젝시믹스, 올웨이즈, 무신사 스튜디오, 리본즈, and 온누리 스토어. The company plans to use new funding to build a large automated logistics hub, further develop its AI-based arrival-guarantee optimization systems, and expand the 딜리래빗 service area.

Participated · Equity · Mar 2024

Seojinex develops lipid nanoparticle (LNP) delivery technologies based on biodegradable ionizable lipids similar to those used in Pfizer and Moderna vaccines. The company says it has secured an LNP pipeline and claims a next‑generation, 4th‑generation targeted ionizable‑lipid LNP capable of organ targeting. Seojinex has added Ewha Womans University pharmacy professor Lee Hyuk‑jin as CTO and vice‑president to boost commercialization and technical leadership. It is pursuing partnerships with domestic and international gene‑ and cell‑therapy developers to apply its LNPs across multiple therapeutic areas. The company plans to establish large‑scale production processes and to pursue global licensing deals to commercialize its LNP platform. Since founding in September 2020, Seojinex has raised a total of ₩12.5 billion to date.